Corvus Pharmaceuticals (CRVS) has drawn attention after a sharp move in its share price, with the stock showing very large gains over the past month and the past 3 months.

The latest share price of $17.38 comes after a steep recent run, with a 30 day share price return of 115.90% and a 90 day share price return of 95.28%. This has contributed to a year to date share price return of 137.43% and a 1 year total shareholder return of 264.36%, which signals strong momentum despite shorter term pullbacks.

If Corvus has caught your eye, it can help to compare it with other high growth healthcare names. You can start with our screener of 25 healthcare AI stocks.

After such rapid gains and with analysts’ price targets sitting well above the current US$17.38 level, the key question now is whether Corvus is still undervalued or if the market is already accounting for future growth in the price.

Preferred Price to Book Multiple of 20.3x: Is It Justified?

Corvus is trading at a P/B of 20.3x, which looks expensive when you set it against both its peers and the wider US biotechs industry.

The P/B ratio compares the company’s market value to the book value of its net assets. A higher multiple usually implies that investors are pricing in strong future value creation beyond today’s balance sheet. For a clinical stage biopharma business with no meaningful revenue and ongoing losses, that typically reflects expectations around the potential of its pipeline rather than current fundamentals.

In this case, Corvus is flagged as expensive with a 20.3x P/B compared to a 3.9x average for its peer group and 2.6x for the broader US biotechs industry. That is a sizeable premium. Anyone looking at the stock will likely want to consider whether the company’s clinical assets and revenue growth forecasts justify paying several times the P/B levels seen elsewhere in the sector.

Result: Preferred price to book multiple of 20.3x (OVERVALUED)

However, there are clear risks, including ongoing losses of US$15.075m and the chance that clinical trials for key drug candidates do not deliver the expected results.

Another Way to Look at Value

While the 20.3x P/B suggests Corvus is expensive next to peers and the wider US biotechs group, our DCF model points in the opposite direction, with an estimated future cash flow value of $55.85 versus the current $17.38 price. That gap hints at upside, but also raises a question: which view do you trust more when the company is still loss making?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Corvus Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 56 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

All of this paints a mixed picture, with both concerns and reasons for optimism, so it is worth stepping through the data yourself and forming your own view. To see how the upside and downside stack up, take a look at our breakdown of 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Corvus feels interesting but you want a broader watchlist, it is worth lining up a few other ideas now so you do not miss what fits you best.

• Scan for potential bargains by checking our list of 56 high quality undervalued stocks that pair appealing price tags with stronger fundamentals.
• Focus on stability and sleep easier at night by reviewing a 81 resilient stocks with low risk scores that screens for companies with more resilient profiles.
• Hunt for underfollowed opportunities by pulling up a screener containing 24 high quality undiscovered gems that highlights high quality names still flying under most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.